TNFA — TNF Pharmaceuticals Share Price
Last trade - 00:00- $2.04m
- -$6.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.14 | ||
| Price to Tang. Book | 0.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -68.4% | ||
| Return on Equity | -197.58% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel oral therapies for autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that is being developed to treat age-related illnesses such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). MYMD-1 can also treat autoimmune diseases, including (but not limited to) multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, and a monoamine oxidase enzyme (MAO) type B.
Directors
- Joshua Silverman CHM (50)
- Chris Chapman PRE (68)
- Ian Rhodes CFO (48)
- Paul Rivard EVP (50)
- Adam Kaplin CSO (54)
- Craig Eagle DRC
- Jude Uzonwanne DRC
- Bill White IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 19th, 2023
- Public Since
- July 24th, 2008
- No. of Shareholders
- 735
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,132,619
- Address
- 1185 Avenue Of The Americas, Suite 249, NEW YORK, 10036
- Web
- https://tnfpharma.com/
- Phone
- +1 8568488698
- Auditors
- Morison Cogen, LLP
Upcoming Events for TNFA
Similar to TNFA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 23:43 UTC, shares in TNF Pharmaceuticals are trading at $0.20. This share price information is delayed by 15 minutes.
Shares in TNF Pharmaceuticals last closed at $0.20 and the price had moved by -93.81% over the past 365 days. In terms of relative price strength the TNF Pharmaceuticals share price has underperformed the S&P500 Index by -94.42% over the past year.
There is no consensus recommendation for this security.
Find out moreTNF Pharmaceuticals does not currently pay a dividend.
TNF Pharmaceuticals does not currently pay a dividend.
TNF Pharmaceuticals does not currently pay a dividend.
To buy shares in TNF Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.20, shares in TNF Pharmaceuticals had a market capitalisation of $2.04m.
Here are the trading details for TNF Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TNFA
Based on an overall assessment of its quality, value and momentum TNF Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TNF Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -84.8%.
As of the last closing price of $0.20, shares in TNF Pharmaceuticals were trading -82.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The TNF Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
TNF Pharmaceuticals' management team is headed by:
- Joshua Silverman - CHM
- Chris Chapman - PRE
- Ian Rhodes - CFO
- Paul Rivard - EVP
- Adam Kaplin - CSO
- Craig Eagle - DRC
- Jude Uzonwanne - DRC
- Bill White - IND